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Summary
In nearly every multifactorial human disease, there are three periods that characterize our
understanding and definition. First, there is a period in which there is rapid accumulation of
descriptive data. Second, there is a longer and slower period as information is obtained that redefines
and expands basic and clinical knowledge that lacks the final and important area of understanding
aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the
vigorous definition of pathobiology and treatment. These phases are well illustrated by our current
understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago
and for the first 40 or so years, the primary research efforts were directed at clinical definitions and
pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of
the immune response and, in particular, a better understanding of anti-mitochondrial antibodies.
These efforts have greatly helped in our understanding of not only the effector mechanisms of disease,
but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has
still not led to successful translation for specific therapy.
Introduction
The history of our knowledge on primary biliary cirrhosis (PBC) focused on four major areas
of research, i.e. diagnosis and clinical management, treatment and natural history, genetics,
and immunopathology. However, these areas have been progressing at very different paces
since the first use of the term PBC almost 60 years ago (1) and the subsequent description of
the first patient series (2). Similar to all complex diseases recognizing multiple pathogenetic
factors, research in PBC begun over 30 years ago with descriptive data. Further, evidence in
each of the four major fields in PBC research has then witnessed rapid and slow progression
rates during the past decades. In this review article, we will critically review the available data
by highlighting the first two phases to ultimately encourage vigorous efforts aimed at
completing the remaining unfinished business in PBC research and cure.
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The diagnosis of PBC
The history and developments in the diagnosis of PBC well resemble the proposed two phases
of experimental data (Table 1). Indeed, the first rapid phase is represented by the earlier major
discoveries, i.e. the description of AMA specificity (3) and the establishment of solid diagnostic
criteria. Nevertheless, further studies in the field have led to the progressive reduction of the
AMA-negative subgroup, yet it remains to be determined whether this fraction of PBC cases
represents a technical limitation of current methods or is indeed a distinct subpopulation with
different serology.
Most of the epidemiologic data used to determine the incidence and prevalence rates of PBC
are descriptive (4). PBC is considered to be most prevalent in England, Scandinavia and in
Northern areas of the United States, although a factitious prevalence due to more exhaustive
epidemiological studies from these countries cannot be excluded. Indeed, prevalence rates for
PBC appear to vary widely in different geographical areas and have been reported to be as high
as 402/million in the Northern US (5), thus making PBC a rare disease according to the 2002
Rare Disease Act. PBC epidemiology is often based on different case-finding methods and
data are thus difficult to compare, yet the concept of a PBC geoepidemiological pattern has
been supported also by anedoctal reports of disease clustering (6,7). Hence, there is the need
of rigorous population-based studies in different geographical areas that do not imply selection
bias, as in the case of blood donors (8), or solid case-finding methods.
Similar to the majority of autoimmune diseases, PBC manifests a striking predominance in the
female sex. In fact, women with PBC are found to outnumber men by as much as 9:1, although
such gender ratio varies widely in different epidemiological studies (4) with the largest non
population-based study thus far reporting a 8:1 ratio (9).
Currently, the diagnosis of PBC is based on the presence of two out of three internationally
accepted criteria, i.e. detectable serum AMA (titer ≥1:40), increased enzymes indicating
cholestasis (i.e. alkaline phosphatase) for longer than 6 months, and a compatible or diagnostic
liver histology (10). The classification proposes that a ‘definite’ diagnosis occurs only when
all three criteria are encountered. We believe this is too narrow as patients lacking serum AMA
appear to follow a similar natural history when compared to their AMA-positive counterparts
(11). Although the need for a liver biopsy remains critical for disease staging, the issue of
whether a liver biopsy is needed upon presentation is still debated. Currently, a liver biopsy
should be performed when only one of the other two diagnostic criteria is met while its need
should be carefully evaluated in the presence of serum AMA positivity and a biochemical
cholestatic pattern for over 6 months. However, it remains to be determined whether liver
histology should be obtained in the presence of serum AMA without elevated alkaline
phosphatase.
The recent development in our laboratory of a sensitive bead assay able to detect AMA in 20%
of otherwise AMA-negative sera (12) strengthens the hypothesis that AMA-negative PBC
cases are secondary to limits in the current testing methods and do not represent an independent
clinical entity. On the other hand, specific patterns of anti-nuclear antibodies (ANA) have
proven to be PBC-specific (13) and are helpful tools in the management of patients with PBC,
particularly when lacking AMA. From this point of view, however, prospective data on their
diagnostic significance and their prevalence in AMA-negative cases are awaited. Another issue
in the diagnosis of PBC includes the consistent finding of elevated serum IgM levels that do
not correlate with AMA titers or disease stage yet appear to decrease when UDCA is used
(14).
These observations on the PBC diagnostic process leads to the important question of what type
of patients should be suspected of having PBC. This is not of secondary importance since an
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early diagnosis appears to be crucial to the efficacy of available medical treatment, i.e.
ursodeoxyhcolic acid (UDCA), which is virtually absent in advanced stages. The diagnosis of
PBC is commonly made in asymptomatic subjects in which routine tests have demonstrated
elevated alkaline phosphatase levels and further analyses are consistent with earlier stages. Our
series of over 400 patients followed at the San Paolo School of Medicine of the University of
Milan over the past 30 years reflects this observation. The proportion of new PBC cases
presenting to our attention with jaundice decreased dramatically from 50% in the 1973-1979
period to less than 5% in the 1992-1997 years and is currently an exceptional event in our
practice with over 80% being diagnosed in the absence of symptoms. Indeed, classically
described symptoms for PBC include fatigue and pruritus (10). The former complaint is, in
our experience, poorly specific and we are convinced that rigorous prevalence studies taking
into account the pre-diagnosis status and the use of well selected controls should be encouraged
to minimize spurious findings. Indeed, somehow conflicting data have been reported on fatigue
(15,16) or quality of life impairment (17,18) but their comparisons remain difficult due to social
differences and the use of various questionnaires.
What should come next? The awaited third phase is represented, in our opinion, by the
overcoming of current histological and serological limitations, possibly through the use of non-
invasive diagnostic tools and the use of 100% sensitive AMA tests. Lastly, the diagnostic role
of PBC-specific ANA has not been fully developed (13) and may hold the key to autoantibody
markers to better define patients with PBC.
The natural history and treatment options of PBC
Several open questions remain in the treatment and natural history of PBC and represent the
awaited third phase in this research area (Table 2). Indeed, the disease progression may vary
widely and it is not uncommon in clinical practice to observe patients remaining asymptomatic
for numerous years and decades and others progressing rapidly to liver failure and liver
transplantation. Earlier evidence of UDCA efficacy and the use of the Mayo score first led to
believe that the solution to PBC prognosis and treatment was at hand, yet the following studies
have progressed slowly, as well represented by the weak results obtained with UDCA-based
combination treatments. What causes PBC severity and progression of the disease remains
unknown, although data seem to indicate that genetic factors other than those inducing the
disease might play a role (19). Among non genetic factors, our group and others have recently
proposed, based on cross-sectional (20) and longitudinal (21,22) studies, that PBC-specific
ANA are associated with a more aggressive disease. This was of particular interest in the
comparison with established prognostic scores such as the Mayo score (23). This score is the
only validated and widely utilized (24) based on clinical and biochemical variables as
represented by cholestasis and liver function, thus possibly being less helpful in early stages
when no hyperbilirubinemia is observed (22). When symptomless at diagnosis, PBC is
associated with 10-year survival rates similar to age- and sex- matched healthy individuals
while 67% of pre-cirrhotic patients will develop liver cirrhosis over a 7-year observation period
while 70% of asymptomatic patients will develop symptoms. Based on these data, it has been
hypothesized that survival rates of asymtpomatic patients with PBC is shorter than the general
population if symptoms develop during follow-up (25) and this may be secondary to non liver
related deaths (26).
UDCA mechanism of action in PBC remains incompletely understood but it has been
hypothesized that it is based on several factors, including stimulation of impaired secretion of
the bile-acid pool, reduction in proinflammatory cytokines, effects on apoptosis and on
vasoactive mediators (27-29). Doses ranging from 13 to 15 mg/kg of UDCA are currently
recommended and lead to optimum bile enrichment while the use of doses as high as 30-40
mg/kg/day as recommended in primary sclerosing cholangitis is currently not supported in
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PBC. A meta-analysis demonstrated that an increased survival is obtained only when a dose
>13 mg/kg is prescribed (30) despite the fact that a complete biochemical response to UDCA
is achieved in approximately 40% of treated patients. We note, however, that the definition of
complete UDCA response should be a priority for future research. Indeed, a complete
biochemical response to UDCA as normalization of alkaline phosphatase levels is suggested
as a major determinant of UDCA effectiveness on disease progression (31).
Immunosuppressive and antifibrotic drugs have been also used in PBC with poor efficacy
(32). The use of corticosteroids is encouraged in combination with UDCA when an overlap
with autoimmune hepatitis is present. New monoclonal antibodies and hematopoietic stem cell
transplantation may be promising in PBC. Liver transplantation is the optimal treatment for
end-stage PBC (33) despite common recurrence (34) influenced by immunosuppressive
regimens and the recipient sex (35).
The etiology of PBC: genetics and environment
The current hypothesis on PBC onset states that the disease results from an environmental
insult intervening on a genetically susceptible background. It is also clear that genetic
components of PBC development cannot be related to a single gene mutation as the disease
does not manifest a complete concordance in monozygotic twin sets (36). Indeed, data on the
genetics of PBC are so far derived only from case-control studies (37) and this approach is
clearly limited by control matching criteria and sample size and selection. Based on these data,
PBC familial occurrence and twin concordance well represent the first (descriptive) phase of
research efforts while the plethora or following association studies represent a slower
progression rate (Table 3).
The concordance rates in monozygotic twins for late-onset autoimmune diseases range are on
average well below 50%. We reported that concordance rates for PBC are 63% in 8
monozygotic sets and null in dizygotic twins (36). It is of interest to note that in some cases
the natural history of PBC as well as the comorbidities vary significantly between concordant
twins. The phenotypical discordance could be caused by epigenetic factors, differences in
exposure to environmental factors such as infections or xenobiotics, as illustrated below, as
well as serendipity. Consistent with twin data, we note the occurrence of multiple cases among
family member (i.e. ‘familial PBC’) with different prevalence rates (38) and the resulting risk
for first-degree relatives of PBC cases to develop the disease (9) or to manifest serum AMA
positivity (39).
Significant associations with specific major histocompatibility complex (MHC) alleles have
been reported in many autoimmune diseases (40) while data in PBC have been conflicting.
The example of the MHC class II DRB8 positive association is paradigmatic in the fact that
this has been repeatedly suggested without achieving universal agreement. In our Milan case
series, this association was not confirmed when smaller patient and control series were used
(41) while the study of the largest population of patients and controls demonstrated a significant
association with the DR8 allele (42,43). Other association studies have investigated the
importance of class III MHC and other candidate genes in determining PBC onset but, once
again, associations have proven to be weak or failed independent confirmation (44).
A susceptible genetic background is necessary, yet not sufficient, to induce PBC. Among
environmental candidates, evidence has been obtained for bacteria and xenobiotics. Of the
bacterial strains suggested to lead to PBC through molecular mimicry (45), most evidence has
been reported for Escherichia coli, based on the reports of an increased prevalence of urinary
tract infections in patients with PBC (9). Contrasting evidence has been collected on the role
of Chlamydia pneumoniae (46,47) and Helicobacter pylori (48-50) in the pathogenesis of PBC
while data on Lactobacillus delbruekii are promising and await further confirmation (51). We
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have recently provided serological data suggesting that a ubiquitous xenobiotic-metabolizing
Gram-negative bacterium, Novosphingobium aromaticivorans, is the best candidate yet for the
induction of PBC, as it elicits a specific antibody-reaction (estimated to be 100 to 1,000-fold
higher than against E. coli) and its 16S rRNA specific sequences were detected in human fecal
samples (52). Most recently, our group has contributed to determine that the infection by N.
aromaticivorans induces PBC-like autoantibodies, autoreactive T cells, and liver lesions
(53).
Xenobiotics are foreign compounds that may either alter or complex to defined self or non-
self proteins, inducing a change in the molecular structure of the native protein sufficient to
induce an immune response leading to chronic autoimmunity. Specific organic structures
attached to the mitochondrial antigens are recognized by PBC sera with a higher affinity than
the native forms of such antigens (54-56). Further, an halogenated compound is capable to
induce AMA production (57) and PBC-like liver lesions (58) in animal models.
One current hypothesis may conjugate the evidence obtained for N. aromaticivorans and
xenobiotics and, if proven, may prompt a new research impulse. The microorganism enters the
human system through the digestive mucosa and bacterial mimics containing lipoic acid
residues at this point might be modified by xenobiotics to form immunoreactive adducts which
activate local dendritic cells. Antigen presenting cells may in turn activate autoreactive T and
B cells that are directed to the liver through the portal system. T cells participate directly in the
autoimmune injury and/or further recruit autoreactive lymphocytes. B cells, on the other hand,
secrete AMA, particularly of the IgA type. AMA IgA are then transported to the vascular side
of the bile duct cell where they react with the PDC-E2-like molecules located on the luminal
surface cell membrane and induce apoptosis. The immune complexes of post-apoptotic PDC-
E2 and IgG-AMA and the direct cytopathic effects of autoreactive T cells (and possibly AMA)
contribute to the tissue injury observed in PBC.
The immunobiology of PBC
Since the determination of PBC autoantigens in 1987 (3) there has been an enormous number
of experimental studies on the major components of PBC autoimmunity. With the exception
of AMA and autoreactive T cells, data on other cell populations are of uncertain significance
in PBC pathogenesis (Table 4). First, it is well established that AMA are directed against
members of the 2-oxoacid dehydrogenase complexes (2-OADC), among which the major
epitopes are within the lipoylated domains of the E2 subunit of the pyruvate dehydrogenase
complex (PDC-E2) (59). The pathogenic role of AMA remains debated since no clinical
correlation can be found and animal models developing serum AMA do not consistently
manifest PBC-like liver lesions. Second, autoreactive CD4+ and CD8+ T cells can be detected
in PBC peripheral blood, regardless of the AMA status, and the infiltration of autoreactive T
cells in the liver and periductular spaces is one of the most prominent immune features (60).
Autoreactive T cells of both subtypes recognize PDC-E2 sequences overlapping with the AMA
epitopes (61). An increase in cytotoxic T cell precursors in the blood in the early stages of the
disease compared to the advanced ones and a 10-fold increase of specific liver CD8+ T cells
compared to peripheral blood have been demonstrated (62). Third, additional data on the
immunobiology components of PBC autoimmunity has been recently obtained in CD4
+CD25 high natural regulatory T cells which appear to be numerically reduced in PBC (63).
What drives the immune mediated response to a ubiquitous antigen to damage a single cell
type with such specificity remains unknown. The identification of specific characteristics of
BEC (64,65) such as the differential expression of cell adhesion molecules, the response to
cytokines and growth factors and their potential ability to act as antigen presenting cells, may
explain the strict organ specificity of the immune mediated injury in PBC (66). PBC bile duct
cells manifest unique features during apoptosis while co-culture experiments do not support a
Selmi et al. Page 5
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
direct role for these cells in determining their immune –mediated injury (67). Indeed, Odin and
colleagues first reported that glutathionylation of the lysine lipoic acid moiety of PDC-E2 is
dramatically reduced via Bcl-2 by serum AMA (68). The enhanced glutathionylation, linked
to the evidence that PDC-E2 is released from apoptotic BEC without caspase cleavage, appears
fundamental in the recognition of the mitochondrial epitope by the immune system upon cell
death. A possible unifying hypothesis has been proposed by Allina and colleagues who recently
demonstrated that apoptotic cells are phagocytosed by BECs and consequently are an
exogenous source of autoantigens in cholangiocytes (69), possibly through anti-CD16 (70).
As a result, the impact of putative changes in apoptosis (71) and autophagy (72) specific to
BEC remains to be fully determined in PBC. Fifth, the innate immune compartment has been
recently investigated in PBC with promising results. PBC monocytes manifest an increased
response to pathogen associated stimuli, as indicated by higher levels of pro-inflammatory
cytokines (73). Further, the hyper-IgM associated with PBC is secondary to an aberrant innate
immune response, potentially induced by stimulation of toll like receptor 9 by bacterial CpG-
B (74). Similarly, Chuang and colleagues reported a marked increase in the frequency and
absolute number of blood and liver NK cells in PBC cases (75).
As summarized in Table 4, we currently have access to a significant amount of descriptive and
partially mechanistic information on the immune alterations associated with PBC. One
hypothesis for the selective destruction of cholangiocytes is based on the aberrant expression
of PDC-E2 on the cell surface, possibly secondary to cell-specific overexpression or to
abnormal intracellular turnover. Although it cannot be ruled out that observed reactivities are
in fact due to immune complexes, it remains possible that the molecules expressed on the
ductular surface may not be PDC-E2 itself, but PDC-E2 mimics. Interestingly, IgA from
patients with PBC colocalize with PDC-E2 (or PDC-E2 mimic) on the apical membrane of
PBC cholangiocytes (76) and these data are consistent with the epithelium-specific damage.
Of mice and women: new players may provide new research impetus
During the past 4 years, new intriguing scenarios have been proposed with important
implications for PBC and the resulting working hypothesis on PBC etiology and pathogenesis
is summarized in Figure 1. These include new evidence on sex chromosomes and novel
comprehensive animal models.
First, the female preponderance may hold an important key to PBC aetiology. The hypotheses
based on sex hormone influence on lymphocytes at various stages in life (77-79) or fetal
microchimerism (80) are inconclusive. X-linked genes determine gender-related
characteristics at different levels while also regulating the immune function, particulalry to
maintain tolerance. Major X chromosome defects such as those leading to Turner's syndrome
(81) or premature ovarian failure (82) are commonly characterized by autoimmune
comorbidities (particularly thyroid disease) and, less frequently, cholestasis. Our group first
determined a significantly higher frequency of monosomy of the X chromosome in peripheral
leukocytes (particularly those of the adaptive immune response, i.e. T and B cells) in women
PBC (36) compared to age-matched control women. Monosomy frequency correlated with age
in all three groups, as expected (83) but monosomic cells were not microchimeric cells (84).
Importantly, women with two other female-predominant and late-onset autoimmune diseases
with different organ specificity, i.e. systemic sclerosis and autoimmune thyroiditis, also
manifested the same difference (85). This was not recapitulated in women with systemic lupus
erithematosus which, however, were significantly younger (86). We further demonstrated that
the X loss in PBC affected was not random but affected more frequently one parentally-
inherited chromosome (87). We submit that the sex chromosome hypothesis is indeed
fascinating (88) and encourage independent researchers to recapitulate our data on other patient
series.
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The second important development during the past few years has been the appearance of three
animal models that may contribute to elucidating the undoubtedly multi-factorial causation
and progression of PBC (89). First, a genomic variant of the non obese diabetic (NOD) mouse
(NOD.c3c4) has been observed to manifest autoimmune cholestasis with AMA and ANA
positivities in 50%–60% and 80%–90%, respectively. Liver histology demonstrated portal
lymphocyte infiltration with chronic non-suppurative cholangitis and PBC-like granulomas
(90). Second, a dominant negative form of trasforming growth factor β (TGFβ) receptor II
(dnTGFβRII) mouse develop serum AMA in 100% of mice. The TGFβ receptor II regulates
lymphocyte activation and the appearance of PBC in this model suggests a specific condition
of T cells with impaired TGFβ signaling in the presence or absence of B cells is involved
(91). Third, the knockout of interleukin 2 receptor α leads to a murine phenotype with 100%
serum AMA positivity, 80% serum ANA positivity, and portal lymphocyte infiltration and
vanishing bile ducts (92). This model is of particular interest based on the report of autoimmune
cholangitis in a pediatric case of IL2Rα deficiency (93).
There appears to be a new excitement caused by these most recent lines of evidence among
researchers involved in PBC aetiopathogenesis. Indeed, we are also convinced that the
appearance of novel laboratory tools such as genome-wide multiplex analysis methods capable
of providing high-throughput analyses of genetic polymorphisms or microRNA will prompt
research efforts to finally determine the genetic bases of PBC. Nevertheless, only a multicenter
study to collect a large number of PBC cases and well-matched controls and to recapitulate
available evidence will provide enough power for the next needed phase in PBC.
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List of Abbreviations
AIH  
autoimmune hepatitis
AMA  
antimitochondrial antibody
APC  
antigen presenting cell
BEC  
biliary epithelial cell
BSA  
bovine serum albumin
CFA  
complete Freund's adjuvant
HLA  
human leukocyte antigens
MHC  
major histocompatibility complex
OADC  
2-oxo-acid dehydrogenase complex
Selmi et al. Page 7
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
PBC  
primary biliary cirrhosis
PBMC  
peripheral blood mononuclear cell
PDC-E2  
E2 subunit of the pyruvate dehydrogenase complex
PSC  
primary sclerosing cholangitis
TGF  
transforming growth factor
References
1. Ahrens, EH., Jr; Payne, MA.; Kunkel, HG.; Eisenmenger, WJ.; Blondheim, SH. Medicine (Baltimore).
29. 1950. Primary biliary cirrhosis; p. 299-364.
2. Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology
1959;37:574–586. [PubMed: 14445875]
3. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding
the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525–
3531. [PubMed: 3571977]
4. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary
biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005;25:265–280.
[PubMed: 16143943]
5. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology
and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631–
1636. [PubMed: 11113084]
6. Abu-Mouch S, Selmi C, Benson GD, Kenny TP, Invernizzi P, Zuin M, et al. Geographic clusters of
primary biliary cirrhosis. Clin Dev Immunol 2003;10:127–131. [PubMed: 14768943]
7. Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, et al. Increased prevalence of
primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006;43:525–531. [PubMed:
16496326]
8. Mattalia A, Quaranta S, Leung PS, Bauducci M, Van de Water J, Calvo PL, et al. Characterization of
antimitochondrial antibodies in health adults. Hepatology 1998;27:656–661. [PubMed: 9500690]
9. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities
in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology
2005;42:1194–1202. [PubMed: 16250040]
10. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261–1273. [PubMed:
16177252]
11. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the
clinical features and clinical course of antimitochondrial antibody-positive and -negative primary
biliary cirrhosis. Hepatology 1997;25:1090–1095. [PubMed: 9141422]
12. Oertelt, S.; Rieger, R.; Selmi, C.; Invernizzi, P.; Ansari, AA.; Coppel, RL., et al. Hepatology. 45.
2007. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative
primary biliary cirrhosis; p. 659-665.
13. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary
biliary cirrhosis. Semin Liver Dis 2005;25:298–310. [PubMed: 16143945]
14. Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, et al. Long-term effects of
ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric
trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol
2000;32:561–566. [PubMed: 10782903]
Selmi et al. Page 8
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
15. Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue is not a specific symptom in patients with
primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005;17:351–357. [PubMed: 15716661]
16. Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a
geographically defined primary biliary cirrhosis patient cohort. Gut 2006;55:536–541. [PubMed:
16299032]
17. Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J. Quality of life in patients with
primary biliary cirrhosis. Hepatology 2004;40:489–494. [PubMed: 15368455]
18. Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, et al. Quality of life and
everyday activities in patients with primary biliary cirrhosis. Hepatology 2007;46:1836–1843.
[PubMed: 18027862]
19. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene
polymorphisms in primary biliary cirrhosis: associations with disease progression and disease
susceptibility. Gut 2001;48:397–402. [PubMed: 11171832]
20. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies
against nuclear pore complexes are associated with more active and severe liver disease in primary
biliary cirrhosis. J Hepatol 2001;34:366–372. [PubMed: 11322196]
21. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer
to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol
2005;42:386–392. [PubMed: 15710222]
22. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of
initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology
2006;43:1135–1144. [PubMed: 16628641]
23. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary
cirrhosis: model for decision making. Hepatology 1989;10:1–7. [PubMed: 2737595]
24. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-
validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability.
Hepatology 1989;10:846–850. [PubMed: 2680867]
25. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary
cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999;94:47–53. [PubMed:
9934730]
26. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis:
clinical features, prognosis, and symptom progression in a large population based cohort. Gut
2004;53:865–870. [PubMed: 15138215]
27. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use
in hepatobiliary disorders’. J Hepatol 2001;35:134–146. [PubMed: 11495032]
28. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid
in cholestatic liver disease. Clin Liver Dis 2004;8:67–81. [PubMed: 15062194]
29. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat
Clin Pract Gastroenterol Hepatol 2006;3:318–328. [PubMed: 16741551]
30. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst
Rev. 2002CD000551
31. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis
and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715–720. [PubMed:
16530513]
32. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, et al. Methotrexate (MTX) plus
ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology
2005;42:1184–1193. [PubMed: 16250039]
33. Williams R, Gershwin ME. How, why, and when does primary biliary cirrhosis recur after liver
transplantation? Liver Transpl 2007;13:1214–1216. [PubMed: 17763403]
34. Batts KP, Wang X. Recurrence of primary biliary cirrhosis, autoimmune cholangitis and primary
sclerosing cholangitis after liver transplantation. Clin Liver Dis 1998;2:421–435. [PubMed:
15560041]
Selmi et al. Page 9
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
35. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, et al. Long-
term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis
after liver transplantation. Liver Transpl 2007;13:1236–1245. [PubMed: 17763401]
36. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. Frequency of monosomy
X in women with primary biliary cirrhosis. Lancet 2004;363:533–535. [PubMed: 14975617]
37. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91–99.
[PubMed: 11253062]
38. Brind AM, Bray GP, Portmann BC, Williams R. Prevalence and pattern of familial disease in primary
biliary cirrhosis. Gut 1995;36:615–617. [PubMed: 7737573]
39. Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, et al. Increased
prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary
cirrhosis. Hepatology 2007;46:785–792. [PubMed: 17680647]
40. McCluskey J, Peh CA. The human leucocyte antigens and clinical medicine: an overview. Rev
Immunogenet 1999;1:3–20. [PubMed: 11256570]
41. Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, et al. Peculiar HLA
polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003;38:401–406.
[PubMed: 12663229]
42. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, et al. HLA class
II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study.
Hepatology 2006;44:667–674. [PubMed: 16941709]
43. Invernizzi P, Selmi C, Poli F, Bianchi I, Rosina F, Floreani A, et al. HLA-DRB1 polymorphisms in
676 Italian patients with primary biliary cirrhosis and 2028 matched healthy controls. A nationwide
population-based case-control study. Hepatology 2005;42:64964.
44. Donaldson PT. TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal. J Hepatol
1999;31:366–368. [PubMed: 10453954]
45. Selmi C, Gershwin ME. Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr
Opin Rheumatol 2004;16:406–410. [PubMed: 15201604]
46. Abdulkarim AS, Petrovic LM, Kim WR, Angulo P, Lloyd RV, Lindor KD. Primary biliary cirrhosis:
an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004;40:380–384. [PubMed:
15123349]
47. Leung PS, Park O, Matsumura S, Ansari AA, Coppel RL, Gershwin ME. Is there a relation between
Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol 2003;10:227–233. [PubMed:
14768955]
48. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter
pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human
liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin
Microbiol 2000;38:1072–1076. [PubMed: 10698999]
49. Nilsson I, Kornilovs'ka I, Lindgren S, Ljungh A, Wadstrom T. Increased prevalence of seropositivity
for non-gastric Helicobacter species in patients with autoimmune liver disease. J Med Microbiol
2003;52:949–953. [PubMed: 14532338]
50. Durazzo M, Rosina F, Premoli A, Morello E, Fagoonee S, Innarella R, et al. Lack of association
between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis. World J
Gastroenterol 2004;10:3179–3181. [PubMed: 15457568]
51. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary
cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope
and its Lactobacillus mimic. Hepatology 2005;42:458–465. [PubMed: 16025495]
52. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. Patients with primary
biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology
2003;38:1250–1257. [PubMed: 14578864]
53. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, et al. Liver autoimmunity triggered
by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304–315. [PubMed:
18474357]
Selmi et al. Page 10
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
54. Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, et al. Immunoreactivity of
organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with
primary biliary cirrhosis. J Immunol 2001;167:2956–2963. [PubMed: 11509645]
55. Rieger R, Leung PS, Jeddeloh MR, Kurth MJ, Nantz MH, Lam KS, et al. Identification of 2-nonynoic
acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun
2006;27:7–16. [PubMed: 16876981]
56. Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun
2007;28:76–84. [PubMed: 17360156]
57. Leung PS, Quan C, Park O, Van de Water J, Kurth MJ, Nantz MH, et al. Immunization with a
xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial
antibodies. J Immunol 2003;170:5326–5332. [PubMed: 12734383]
58. Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, Ansari AA, et al. Induction of primary biliary
cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007;179:2651–
2657. [PubMed: 17675529]
59. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, et al. Primary biliary
cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210–
225. [PubMed: 10807518]
60. Ishibashi H, Nakamura M, Shimoda S, Gershwin ME. T cell immunity and primary biliary cirrhosis.
Autoimmun Rev 2003;2:19–24. [PubMed: 12848971]
61. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted
immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis:
evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835–1845.
[PubMed: 7536796]
62. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification
and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in
primary biliary cirrhosis. J Clin Invest 1998;102:1831–1840. [PubMed: 9819369]
63. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, et al. Liver-targeted and peripheral
blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729–737.
[PubMed: 16557534]
64. Kanno N, LeSage G, Glaser S, Alvaro D, Alpini G. Functional heterogeneity of the intrahepatic biliary
epithelium. Hepatology 2000;31:555–561. [PubMed: 10706542]
65. Alpini G, Glaser S, Robertson W, Rodgers RE, Phinizy JL, Lasater J, et al. Large but not small
intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. Am J Physiol
1997;272:G1064–G1074. [PubMed: 9176215]
66. Selmi C, Mackay IR, Gershwin ME. The immunological milieu of the liver. Semin Liver Dis
2007;27:129–139. [PubMed: 17520513]
67. Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, et al. Biliary epithelial cells
and primary biliary cirrhosis: The role of liver-infiltrating mononuclear cells. Hepatology
2008;47:958–965. [PubMed: 18181218]
68. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of
pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest
2001;108:223–232. [PubMed: 11457875]
69. Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, et al. T cell targeting and phagocytosis
of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006;27:232–241.
[PubMed: 17222534]
70. Allina J, Stanca CM, Garber J, Hu B, Sautes-Fridman C, Bach N, et al. Anti-CD16 autoantibodies
and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun 2008;30:238–
245. [PubMed: 18023559]
71. Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. The consequences of apoptosis in
autoimmunity. J Autoimmun. 2008in press
72. Lleo A, Invernizzi P, Selmi C, Coppel RL, Alpini G, Podda M, et al. Autophagy: highlighting a novel
player in the autoimmunity scenario. J Autoimmun 2007;29:61–68. [PubMed: 17693057]
Selmi et al. Page 11
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
73. Mao TK, Lian ZX, Selmi C, Ichiki Y, Ashwood P, Ansari AA, et al. Altered monocyte responses to
defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005;42:802–808.
[PubMed: 16175622]
74. Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, Kaplan M, et al. Bacterial CpG induces hyper-
IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology
2005;128:304–312. [PubMed: 15685542]
75. Chuang YH, Lian ZX, Tsuneyama K, Chiang BL, Ansari AA, Coppel RL, et al. Increased killing
activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J
Autoimmun 2006;26:232–240. [PubMed: 16730427]
76. Malmborg AC, Shultz DB, Luton F, Mostov KE, Richly E, Leung PS, et al. Penetration and co-
localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis.
J Autoimmun 1998;11:573–580. [PubMed: 9802945]
77. Rubel LR, Rabin L, Seeff LB, Licht H, Cuccherini BA. Does primary biliary cirrhosis in men differ
from primary biliary cirrhosis in women? Hepatology 1984;4:671–677. [PubMed: 6745856]
78. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev 1984;5:435–455.
[PubMed: 6381037]
79. Parikh-Patel A, Gold E, Utts J, Gershwin ME. The association between gravidity and primary biliary
cirrhosis. Ann Epidemiol 2002;12:264–272. [PubMed: 11988415]
80. Invernizzi P, De Andreis C, Sirchia SM, Battezzati PM, Zuin M, Rossella F, et al. Blood fetal
microchimerism in primary biliary cirrhosis. Clin Exp Immunol 2000;122:418–422. [PubMed:
11122249]
81. Ranke MB, Saenger P. Turner's syndrome. Lancet 2001;358:309–314. [PubMed: 11498234]
82. Davis CJ, Davison RM, Payne NN, Rodeck CH, Conway GS. Female sex preponderance for idiopathic
familial premature ovarian failure suggests an X chromosome defect: opinion. Hum Reprod
2000;15:2418–2422. [PubMed: 11056145]
83. Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. Sex chromosome loss and aging: in
situ hybridization studies on human interphase nuclei. Am J Hum Genet 1995;57:1143–1150.
[PubMed: 7485166]
84. Kaplan MM, Bianchi DW. Primary biliary cirrhosis: for want of an X chromosome? Lancet
2004;363:505–506. [PubMed: 14975609]
85. Invernizzi P, Miozzo M, Selmi C, Persani L, Battezzati PM, Zuin M, et al. X chromosome monosomy:
a common mechanism for autoimmune diseases. J Immunol 2005;175:575–578. [PubMed:
15972694]
86. Invernizzi P, Miozzo M, Oertelt-Prigione S, Meroni PL, Persani L, Selmi C, et al. X monosomy in
female systemic lupus erythematosus. Ann N Y Acad Sci 2007;1110:84–91. [PubMed: 17911423]
87. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss
but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46:456–462.
[PubMed: 17659578]
88. Invernizzi P. The X chromosome in female-predominant autoimmune diseases. Ann N Y Acad Sci
2007;1110:57–64. [PubMed: 17911420]
89. Oertelt S, Ridgway WM, Ansari AA, Coppel RL, Gershwin ME. Murine models of primary biliary
cirrhosis: Comparisons and contrasts. Hepatol Res 2007;37:S365–S369. [PubMed: 17931188]
90. Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, et al. NOD.c3c4 congenic mice develop
autoimmune biliary disease that serologically and pathogenetically models human primary biliary
cirrhosis. J Exp Med 2006;203:1209–1219. [PubMed: 16636131]
91. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies
and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol
2006;177:1655–1660. [PubMed: 16849474]
92. Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH, et al. IL-2 receptor alpha
(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006;44:1240–1249.
[PubMed: 17058261]
93. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, Shoenfeld Y, et al. IL-2 receptor alpha
deficiency and features of primary biliary cirrhosis. J Autoimmun 2006;27:50–53. [PubMed:
16904870]
Selmi et al. Page 12
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
94. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological Tests in Diagnosis of Primary Biliary
Cirrhosis. Lancet 1965;1:827–831. [PubMed: 14263538]
95. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996;335:1570–1580. [PubMed: 8900092]
96. Miyakawa, H.; Tanaka, A.; Kikuchi, K.; Matsushita, M.; Kitazawa, E.; Kawaguchi, N., et al.
Hepatology. 34. 2001. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-
negative patients with primary biliary cirrhosis using recombinant autoantigens; p. 243-248.
97. Heathcote J. Update on primary biliary cirrhosis. Can J Gastroenterol 2000;14:43–48. [PubMed:
10655026]
98. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in
monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology
2004;127:485–492. [PubMed: 15300581]
99. Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME. Genes and (auto)immunity in
primary biliary cirrhosis. Genes Immun 2005;6:543–556. [PubMed: 16034472]
100. Selmi C, Invernizzi P, Miozzo M, Podda M, Gershwin ME. Primary biliary cirrhosis: does X mark
the spot? Autoimmun Rev 2004;3:493–499. [PubMed: 15546796]
101. Selmi C, Gershwin ME. Bacteria and human autoimmunity: the case of primary biliary cirrhosis.
Curr Opin Rheumatol 2004;16:406–410. [PubMed: 15201604]
102. Lan RY, Mackay IR, Eric Gershwin M. Regulatory T cells in the prevention of mucosal inflammatory
diseases: Patrolling the border. J Autoimmun 2007;29:272–280. [PubMed: 17889505]
Selmi et al. Page 13
J Hepatol. Author manuscript; available in PMC 2009 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
The current working hypothesis of PBC development is illustrated. The primum movens of the
proposed mechanisms is based on the peculiar apoptotic features of biliary epithelial cells
(BEC). Secondary to a reduced glutathiolation (I), apoptotic BEC release an intact PDC-E2
(II) which also includes lipoic acid (III). Lipoic acid in turn becomes the ideal target for
xenobiotic-induced modifications with 2-octynoic acid as the best candidate (IV) and with N.
aromaticivorans possibly influencing this pathway (V). The modified or substituted lipoic acid
residue is then uptaken by antigen presenting cells (VII) and is capable of breaking immune
tolerance (VIII) in the presence of a permissive genetic background. Female predominance of
PBC may be explained by major sex chromosome defects such as X monosomy (IX) or by the
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increased exposure to specific xenobiotics (X). Indeed, individual susceptibility may be based
on on a direct putative impact of a specific set of genes on disease development or progression
(XI), as suggested by association studies, or by epigenetic changes of sex (XII) or somatic
(XIII) chromosomes that remain to be investigated. The ultimate result of a permissive genetic
background and an undertermined environmental exposure is the development and
perpetuation of the PBC liver injury (XIV).
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Table 1
The history of developments observed in PBC diagnosis are well representative of the different discovery paces with
the early major discoveries in PBC diagnosis and the slow progression of newer techniques for AMA testing. Putative
developments for the expected upcoming phases are suggested.
Reference
Phase 1 Earlier breakthrough Proof of AMA specificity (94)
Established diagnostic criteria (95)
Phase 2 Minimizing AMA-negative Use of recombinant antigens (96)
Use of multiplex AMA tests (12)
Phase 3 What is next? 100% specific histology
100% sensitive AMA tests
PBC-diagnostic ANA
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Table 2
PBC natural history and treatment remain an unfinished business. The rapid pace of earlier discoveries well represent
phase 1 and was followed by slower developments with combination treatments and the prognostic significance of
ANA. Future developments in the third phase are hypothesized.
Reference
Phase 1 Earlier breakthrough UDCA efficacy (28)
Mayo score validation (23)
Phase 2 Later developments UDCA combination therapies (97)
ANA prognostic significance (22)
Phase 3 What is next? Definition of UDCA response
Genetic factors in PBC progression
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Table 3
PBC genetic and environmental bases recognize three bases with an earlier rapid development of descriptive data on
familial PBC and twin concordance subsequently followed by a slower phase with unconclusive association studies
while recapitulation of the role of sex chromosome, xenobiotics, and bacteria is awaited. Epigenetic studies may
constitute the key to a awaited third phase.
Reference
Phase 1 Earlier breakthrough Familial PBC (4)
Twin concordance (98)
Risk factors (9)
Phase 2 Later developments HLA/non-HLA associations (99)
X chromosome defects (100)
Bacterial candidates (101)
Xenobiotic reactivity (56)
Phase 3 What is next? Genome-wide association studies
Spontaneous animal models
Epigenetic studies
Recapitulation of bacteria and chemicals
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Table 4
PBC immunobiology was characterized by earlier discoveries leading to the definition of AMA autoantigens and
autoreactive T cells while a second phase is well represented by the study of T regulatory cells, apoptosis in
cholangiocytes, and innate immune changes. The integration of these lines of evidence is the major awaited
development in the third phase.
Reference
Phase 1 Earlier breakthrough Cloning of AMA autoantigens (3)
Definition of autoreactive T cells (61)
Phase 2 Later developments Definition of Treg defects (102)
Bile duct cell apoptosis uniqueness (68)
Innate immune changes in PBC (73,74)
Phase 3 What is next? Proof of apoptosis involvement in autoantigen recognition
Definition of lipoic acid critical role
Recapitulation of all of the above in an animal model
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